SCA
AGN

Snowden Capital Advisors’s Allergan plc AGN Stock Holding History

Snowden Capital Advisors’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,183
Closed -$225K – 516
2018
Q3 		$225K Buy
+1,183
New +$217K 0.03% 449

Other funds holding AGN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Snowden Capital Advisors's AGN Position: Q4 2018 in Review

Snowden Capital Advisors sold out of Allergan plc (AGN) in Q4 2018, closing a stake of 1,183 shares — an estimated $225K sold.

Snowden Capital Advisors first reported a position in AGN in Q3 2018 and held it in 1 quarter. The position peaked at $225K in Q3 2018. 1,007 funds tracked by Wall St. Rank hold AGN as of Q4 2018.

  • Snowden Capital Advisors reported no remaining Allergan plc position as of Q4 2018 after selling out during the quarter.
  • Snowden Capital Advisors sold 1,183 Allergan plc shares in Q4 2018, an estimated $225K.
  • Snowden Capital Advisors first reported a position in Allergan plc in Q3 2018 and held it in 1 quarter.
  • Snowden Capital Advisors's Allergan plc position peaked at $225K in Q3 2018.
  • 1,007 funds tracked by Wall St. Rank held Allergan plc as of Q4 2018.

Based on Snowden Capital Advisors's 13F filing for Q4 2018, filed 8 Jan 2024.